Home Admissions Page 38

Admissions

Latest

PhD Admissions for Chemistry Candidate | CFTRI Recruitment 2026 | Apply Now

Admissions

CSIR-CFTRI PhD Admission 2026 for Chemistry Graduates | Apply for the Govt Vacancy

Diluxi Arya - March 24, 2026

PhD Admissions

Admissions

PhD Admission in Chemistry | IIT Ropar Vacancy 2026

PhD Admission at SRM University | Chemical Science Careers

Admissions

SRM University Careers | PhD Admission for Chemical Science | Fellowship up to Rs. 60,000/- per month

PhD Admissions for Chemistry Graduates at AcSIR | Govt Role

Admissions

Government PhD Admissions for Chemistry Candidates at AcSIR – Apply Now

PhD Admissions in Chemical Science | IISER Mohali Vacancy 2026 | Apply Now

Admissions

IISER Mohali PhD Admissions 2026 | Chemical Science Apply

BITMESRA Phd Program Admission Notification - 2019

Admissions

BIT MESRA Phd Program Admission Notification – 2019

Swarna Khushbu - October 15, 2018 0

NIUS Chemistry Programme @ Homi Bhabha Center, TIFR

Admissions

NIUS Chemistry Programme @ Homi Bhabha Center, TIFR

Swarna Khushbu - September 20, 2018 0

Phd Program Admission For Chemistry & Pharma Candidates @ RGCB

Admissions

Phd Program Admission For Chemistry & Pharma Candidates @ RGCB

Swarna Khushbu - August 21, 2018 0

Admissions

Ph.D. Program Admissions for Chemistry Candidates @ IIT Hyderabad

Rainer Kim - May 5, 2018 0

MTech Chemical Sciences Admissions 2018 @ DIAT

Admissions

MTech Chemical Sciences Admissions 2018 @ DIAT – Defence Institute of...

Shekhar - March 22, 2018 0

PhD Programme Admissions 2018 @ DIAT

Admissions

PhD Programme Admissions 2018 @ DIAT – Defence Institute of Advanced...

Shekhar - March 22, 2018 0

PhD Programme Admissions 2018 @ DIAT

Admissions

Integrated PhD Programme Admissions 2018 @ IISER Pune

Diluxi Arya - March 14, 2018 0

Chemistry Job : Research Fellow Post Vacant @ MANIT Bhopal

Admissions

Integrated PhD Admissions 2018 – Chemistry @ IISER TVM

Rainer Kim - March 6, 2018 0

Pharma Job : Regional Training Manager Post @ JBCPL

Admissions

PhD Admissions August 2018 – Chemical Sciences @ IISER TVM

Rainer Kim - March 6, 2018 0

PhD Programme Admissions 2018 @ DIAT

Admissions

Summer Student’s Programme 2018 (Chemistry) @ IASST

Rainer Kim - March 5, 2018 0

1...373839...42 Page 38 of 42

MOST POPULAR

Smarter Catalyst Turns CO₂ Into Clean Fuel

Scientists Turn CO₂ Into Fuel With a Breakthrough Single-Atom Catalyst

March 24, 2026

Student’s Chemistry Research Creates Touch-Enabled Nail Polish

Breaking News: Student Creates Nail Polish That Lets You Use Touch...

March 24, 2026

Diazo Compounds Uncovered: ‘Dark Matter’ in Lung Bacteria

Diazo Compounds Breakthrough: Scientists Finally See the Unseen

March 24, 2026

Rasayanika Times Newsletter 24.03.2026 - Colgate Palmolive Research Trainee, Freshers Job at Hetero & Emnar Pharma, Govt Job at CIPET & CFTRI salary up to Rs 40,000 & Many More

Rasayanika Times Newsletter 24.03.2026 – Colgate Palmolive Research Trainee, Freshers Job...

March 24, 2026

HOT NEWS

Jr. Research Fellow Post @ IIT Indore

B.sc Chemistry

QA, QC, Production Officer Posts for Chemistry Candidates @ Ipca Laboratories

Both the World Health Organization (WHO) and NIH’s National Heart, Lung, and Blood Institute (NHLBI) have halted hydroxychloroquine's clinical studies conducted to assess the safety and effectiveness of the drug to treat adults with Covid-19 and Novartis, due to its inability to recruit enough patients, ended the Phase III trials of the same drug. One week before, the FDA had revoked its emergency use authorization (EUA) for hydroxychloroquine due to a randomized controlled clinical trial that showed no clinical benefit and the lack of consistent replication of earlier promising results. A data and safety monitoring board (DSMB) found that hydroxychloroquine is not beneficial in treating COVID-19, compared to placebo. However, NIH noted that the drug is not harmful. DSMB recommended the National Heart, Lung, and Blood Institute (NHLBI) to halt the study after a fourth interim analysis. The randomized, blinded, placebo-controlled clinical trial was conducted in more than 500 patients infected with the novel coronavirus, among which 470 were recruited at the time of trial’s closure. 400mg hydroxychloroquine was given twice a day to the participants for two doses, followed by 200mg twice daily for the next eight doses, or a placebo twice daily for five days. Meanwhile, Novartis, a Swiss pharmaceutical company suspended the phase III clinical trials of hydroxychloroquine, as the completion of the trial was infeasible due to enrollment challenges. No conclusions have been made on the efficacy of the drug in treating COVID-19 and no safety issues have been reported, the company noted. Due to the recruitment challenges, the clinical team was unable to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with Covid-19, said Novartis. However, Novartis will continue to supply HCQ upon government requests and for certain ongoing investigator-initiated trials (IITs). Since HCQ showed no benefit compared to standard of care in reducing deaths, the World Health Organization also halted the clinical trials of hydroxychloroquine on June 17. Source

News

NIH, WHO And Novartis Ended Hydroxychloroquine Trials For COVID-19

Clinical Research Coordinator Job at SJRI Apply by May 27

Jobs

Freshers Clinical Research Job For Pharm D at SJRI – Apply...

Syngene Analytical Chemistry

B.sc Chemistry

Syngene Analytical Chemistry/ Pharma Executive Job Opening, Apply Online